Med. praxi. 2014;11(1):9-14

The current and the new pharmacotherapy for hyperlipidemias/dyslipidemias

doc.MUDr.David Karásek, Ph.D.
III. interní klinika LF UP a FN Olomouc

Hyperlipidemias and dyslipidemias (HLP/DLP) represent a heterogenic group of lipid disorders. Cardiovascular events are the most serious

complications of these diseases. Although, efficient and safe drugs (especially statins) are available, the high proportion of cardiovascular

events remains therapeutically unaffected. Currently, an intensive research of drugs modifying levels of LDL-cholesterol, triglycerides

and HDL-cholesterol continues. We can expect some of them to be used in pharmacotherapy for HLP/DLP and to lead to the decrease

of cardiovascular risk of our patients.

Keywords: dyslipidemia, statins, fibrates, nicotinic acid, PCSK 9 inhibitors, mipomersen

Published: February 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek D. The current and the new pharmacotherapy for hyperlipidemias/dyslipidemias. Med. praxi. 2014;11(1):9-14.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Karásek D, Vaverková H. Smíšená dyslipidémie-současné možnosti léčby. Interní Med 2011; 13: 7-12.
    2. Češka, a kol. Cholesterol a ateroskleróza, léčba dyslipidémie. Praha: Triton 2012: 406.
    3. Vrablík M. Jaké nové léky můžeme očekávat v léčbě dyslipidemií? Interní Med 2011; 13: 337-339.
    4. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278. Go to original source... Go to PubMed...
    5. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet 2008; 371: 117-125. Go to original source... Go to PubMed...
    6. Vrablík M. Léčba dyslipidemie a prevence ICHS u diabetiků. In Haluzík M. a kol. Praktická léčba diabetu. Mladá fronta Praha 2013: 234-258.
    7. Ginsbeg H. Statins in cardiometabolic disease: what makes pitavastatin different? Cardiovasc Diabetol 2013; 12(Suppl 1): S1. Go to original source... Go to PubMed...
    8. Steinberg H, Anderson MS, Musliner T, et al. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vasc Health Risk Manag 2013; 9: 273-282. Go to original source... Go to PubMed...
    9. Costet P. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins. Pharmacol Ther 2010; 126: 263-278. Go to original source... Go to PubMed...
    10. Huang LZ, Zhu HB. Novel LDL-oriented pharmacotherapeutical strategies. Pharmacol Res 2012; 65: 402-410. Go to original source... Go to PubMed...
    11. Joy TR. Novel therapeutic agents for lowering low density lipoprotein cholesterol. Pharmacol Ther 2012; 135: 31-43. Go to original source... Go to PubMed...
    12. Do RQ, Vogel RA, Schwartz GG. PCSK 9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 2013; 15: 345. Go to original source... Go to PubMed...
    13. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol 2008; 102: 19L-27L. Go to original source... Go to PubMed...
    14. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 2009; 70: 815-828. Go to original source... Go to PubMed...
    15. Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126: 314-345. Go to original source... Go to PubMed...
    16. Jones PH. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol 2008; 102: 41L-47L. Go to original source... Go to PubMed...
    17. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-1861. Go to original source... Go to PubMed...
    18. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574. Go to original source... Go to PubMed...
    19. Toth PP. Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found. Curr Atheroscler Rep 2010; 12: 331-335. Go to original source... Go to PubMed...
    20. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-122. Go to original source... Go to PubMed...
    21. Chan DC, Pang J, Romic G, et al. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep 2013; 15: 309. Go to original source... Go to PubMed...
    22. Khera AV, Plutzky J. Management of low levels of high-density lipoprotein-cholesterol. Circulation 2013; 128: 72-78. Go to original source... Go to PubMed...
    23. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255. Go to original source... Go to PubMed...
    24. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.